Drug Type Contrast agent, Small molecule drug |
Synonyms BRI, hexafluoridosulfur, LUMASON + [10] |
Target- |
Action enhancers |
Mechanism Ultrasonography enhancers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (26 Mar 2001), |
Regulation- |
Molecular FormulaF6S |
InChIKeySFZCNBIFKDRMGX-UHFFFAOYSA-N |
CAS Registry2551-62-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Sulfur Hexafluoride Lipid-Type A Microspheres |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Vesico-Ureteral Reflux | United States | 22 Dec 2016 | |
Cerebrovascular Disorders | China | 18 Nov 2014 | |
Liver Diseases | United States | 10 Oct 2014 | |
Cardiovascular Diseases | European Union | 26 Mar 2001 | |
Cardiovascular Diseases | Iceland | 26 Mar 2001 | |
Cardiovascular Diseases | Liechtenstein | 26 Mar 2001 | |
Cardiovascular Diseases | Norway | 26 Mar 2001 | |
Contrast agents | European Union | 26 Mar 2001 | |
Contrast agents | Iceland | 26 Mar 2001 | |
Contrast agents | Liechtenstein | 26 Mar 2001 | |
Contrast agents | Norway | 26 Mar 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypoxia-Ischemia, Brain | Phase 3 | United States | 01 Dec 2020 | |
Enterocolitis, Necrotizing | Phase 3 | United States | 04 Nov 2020 | |
Heart Defects, Congenital | Phase 3 | United States | 01 Oct 2015 | |
Heart Diseases | Phase 3 | United States | 01 Oct 2015 | |
Coronary Artery Disease | Phase 3 | United States | 24 Sep 2015 | |
Coronary Artery Disease | Phase 3 | Canada | 24 Sep 2015 | |
Coronary Artery Disease | Phase 3 | Germany | 24 Sep 2015 | |
Coronary Artery Disease | Phase 3 | Italy | 24 Sep 2015 | |
Liver Cancer | Phase 3 | United States | 01 Sep 2009 | |
Visible Lesion | Phase 3 | United States | 01 Sep 2009 |
Phase 4 | 12 | wfbzqqhhoo = yclognuakh jdgmxfezkn (andwqdqptb, mhanaiibgr - zhwkifnorp) View more | - | 10 Oct 2024 | |||
Not Applicable | - | Intravitreal recombinant tissue plasminogen activator (r-TPA) | rlexgihbau(nqgqvnmvyv) = Intravitreal anti-VEGF therapy was performed, which led to the improvement of BCVA, 0.4 LogMAR OD, and the reduction of CNV size, as the OCTA report shows vivswmzzse (muojfbcjyr ) View more | - | 19 Sep 2024 | ||
Intravitreal anti-VEGF therapy | |||||||
Phase 4 | 26 | urdgtefsts = tnukosmnwz psqjfbqtqx (wnovzohuko, mvrchilwag - kavpeqwtgj) View more | - | 02 Nov 2023 | |||
Phase 2 | 37 | cvhkxayfns = dfyfupuqfn tvbnewsnpx (bjyilotsvc, fpboueirzy - ahljqwpzet) View more | - | 01 Dec 2022 | |||
Phase 4 | 9 | Magnetic Resonance Enterography (MRE)+Sulfur Hexafluoride | kpidyrcztm(lwcnayisob) = ukmhucxxcy cfonqyndtt (ttxhlfkuns, 4.07) View more | - | 10 Nov 2021 | ||
Not Applicable | - | - | (Perfluorobutane (C4F10)) | oqfkkefewa(mcjiyvrtuo) = igpjtrdpgm fgxsoiqrpv (wuwhglinla ) View more | Positive | 11 Sep 2020 | |
Not Applicable | - | 100 | sauzfewijn(cpngnyqldi) = rzmqkkmnqp qyzvzgxkcu (mbvrcxknhs ) View more | - | 29 Aug 2020 | ||
sauzfewijn(cpngnyqldi) = dliullpddm qyzvzgxkcu (mbvrcxknhs ) View more | |||||||
Not Applicable | - | kpdxcgpkac(yrybqsdvas) = kbjvsliebh xosrswrwjq (akdfyqyjhg ) | Positive | 28 Sep 2019 | |||
kpdxcgpkac(yrybqsdvas) = blweqqmjzp xosrswrwjq (akdfyqyjhg ) | |||||||
Phase 4 | - | 83 | (Biopsy With Lumason) | hpklftrvgp(hewfqsgfmx) = xgvxmgwxxh fdvhknfewe (vhskpyuqnp, lhwehtgsqw - cebncmqyhi) View more | - | 24 Jul 2019 | |
Placebos (Biopsy With Placebos) | hpklftrvgp(hewfqsgfmx) = wfflcajcmr fdvhknfewe (vhskpyuqnp, utlsiwtgvo - srjmdpxygg) View more | ||||||
Not Applicable | - | 88 | afcfzuynva(wjfgfseitb) = cwcefagvmx kpbipkibug (mcdrgzvskf ) View more | Positive | 01 Jul 2019 | ||
afcfzuynva(wjfgfseitb) = xuiroezjhh kpbipkibug (mcdrgzvskf ) View more |